Total trials
415
Active
68
Phase 3
96
Total enrollment
247,225
Pipeline matrix
Showing 40 of 74 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Trastuzumab deruxtecan | — | — | 22 | ||||
| Pembrolizumab | — | — | — | 8 | |||
| Ifinatamab deruxtecan | — | — | — | 7 | |||
| Paclitaxel | — | — | — | 11 | |||
| Carboplatin | — | — | — | 10 | |||
| Datopotamab Deruxtecan | — | — | — | 5 | |||
| Quizartinib | — | — | 14 | ||||
| Patritumab Deruxtecan | — | — | — | — | 5 | ||
| Cisplatin | — | — | — | 5 | |||
| Chemotherapy | — | — | — | — | — | 4 | |
| T-DXd | — | — | — | — | 3 | ||
| Trastuzumab | — | — | — | — | 4 | ||
| Gemcitabine | — | — | — | — | 3 | ||
| Docetaxel | — | — | — | — | 3 | ||
| Topotecan | — | — | — | — | — | 2 | |
| Pemetrexed | — | — | — | — | — | 2 | |
| Dato-DXd | — | — | — | — | 2 | ||
| Ezetimibe | — | — | 7 | ||||
| Bempedoic acid | — | — | — | 6 | |||
| Rosuvastatin | — | — | — | 5 | |||
| Atorvastatin | — | — | — | 4 | |||
| Pexidartinib | — | 8 | |||||
| DS-8201a | — | — | — | 8 | |||
| Capecitabine | — | — | — | — | 3 | ||
| DS-1062a | — | — | — | — | 2 | ||
| T-DM1 | — | — | — | — | — | 1 | |
| R-DXd | — | — | — | — | — | 1 | |
| PLD | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Endocrine Therapy | — | — | — | — | — | 1 | |
| Palbociclib | — | — | — | — | — | 1 | |
| Ado-trastuzumab emtansine | — | — | — | — | — | 1 | |
| Ramucirumab | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 1 | |
| Eribulin | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Irinotecan hydrochloride | — | — | — | — | — | 1 | |
| Platinum-based chemotherapy | — | — | — | — | — | 1 | |
| Amrubicin | — | — | — | — | — | 1 | |
| Lurbinectedin | — | — | — | — | — | 1 |
34 more active programs hidden
Next readouts
- 2021-01-31
- 2021-05-21
- 2021-10-27
- 2022-01-11
- 2022-11-21
- 2022-12-31
- 2023-03-10
- 2023-05-10
- 2024-04-14
- 2024-05-10
Top conditions
- Hypertension22
- Atrial Fibrillation18
- Type 2 Diabetes Mellitus15
- Essential Hypertension15
- Non-small Cell Lung Cancer12
- Advanced Solid Tumor12
- Venous Thromboembolism11
- Hypercholesterolemia11
Frequently asked questions about Daiichi Sankyo
- How many clinical trials does Daiichi Sankyo have on ClinicalTrials.gov?
- Daiichi Sankyo is listed as the lead sponsor on 415 clinical trials in ClinicalTrials.gov, 68 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Daiichi Sankyo's trials are in Phase 3?
- 96 of Daiichi Sankyo's trials are in Phase 3, spread across 74 active drug programs.
- What therapeutic areas does Daiichi Sankyo focus on?
- Daiichi Sankyo's most-studied conditions on ClinicalTrials.gov are Hypertension, Atrial Fibrillation, Type 2 Diabetes Mellitus, Essential Hypertension, Non-small Cell Lung Cancer.
- When are Daiichi Sankyo's next clinical trial readouts?
- Daiichi Sankyo has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas”, expected around 2021-01-31.